Craig-Hallum raised the firm’s price target on Eton Pharmaceuticals (ETON) to $28 from $26 and keeps a Buy rating on the shares following Q1 earnings, which was another strong performance. The company reiterated an $80M run-rate goal by year-end, though the firm sees this as conservative based on current trends and has modeled slightly above this level.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETON: